<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044743</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1-KO-EBV-CTL</org_study_id>
    <nct_id>NCT03044743</nct_id>
  </id_info>
  <brief_title>PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies</brief_title>
  <official_title>A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yang Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV
      (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be
      collected for research purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin.
      Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response
      are evaluated. Biomarkers and immunological markers are also monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of the normalization of tumor marker</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-γ change of T cells in the peripheral blood stimulated by tumor antigens</measure>
    <time_frame>Baseline and 1 month, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1/Th2 change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stage IV Gastric Carcinoma</condition>
  <condition>Stage IV Nasopharyngeal Carcinoma</condition>
  <condition>T-Cell Lymphoma Stage IV</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>PD-1 knockout EBV-CTL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).
Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.
A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.
Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>To modify immune micro-environment</description>
    <arm_group_label>PD-1 knockout EBV-CTL</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>To modify immune micro-environment</description>
    <arm_group_label>PD-1 knockout EBV-CTL</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>To sustain the survival of infused T cells</description>
    <arm_group_label>PD-1 knockout EBV-CTL</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically verified stage IV gastric carcinoma, nasopharyngeal carcinoma and
             lymphoma with measurable lesions (At least one measurable lesion or the immunotherapy)

          -  Pathologically verified as EBV positive malignancies

          -  Human leukocyte antigen (HLA) genotypes: HLA-A02, HLA-A24 or HLA-A11 genotypes

          -  Progressed after standard treatment or the patients refused to accept the standard
             treatment

          -  Performance score: 0-1

          -  Expected life span: &gt;= 3 months

          -  Toxicities from prior treatment has resolved. Washout period is 1 months

          -  Major organs function normally

          -  Women at pregnant ages should be under contraception

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Patients with possible drug allergy of immunotherapy

          -  Patients with active bacterial or fungal infections

          -  Coagulopathy, or ongoing thrombolytics and/or anticoagulation

          -  Blood-borne infectious disease, e.g. hepatitis B, hepatitis C and HIV

          -  History of coronary artery disease, asthma, or vascular disease or other disease
             inappropriate for treatment deemed by treating physician

          -  With other tumors except for in situ cervical cancer, treated squamous cell carcinoma
             and bladder cancer (Ta and TIS) or other malignancies that have been treated with
             radical therapy (at least for 5 years before the enrollment)

          -  With other immune diseases, or chronic use of immunosuppressants or steroids

          -  Pregnant and lactating women

          -  Compliance cannot be expected

          -  Other conditions requiring exclusion deemed by physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baorui Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baorui Liu, MD</last_name>
    <phone>0086-25-83106666-61331</phone>
    <email>baoruiliu07@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shu Su, MD</last_name>
    <phone>0086-25-83106666-61331</phone>
    <email>ssnine@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Comprehensive Cancer Center of Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Yang, MD,PhD,MSCR</last_name>
      <phone>0086-18602568379</phone>
      <email>wing_young7@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Yan, MD</last_name>
      <phone>0086-15805182426</phone>
      <email>firefreebird@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Comprehensive Cancer Center of Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Yang</last_name>
      <phone>18602568379</phone>
      <email>wing_young7@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kim SY, Park C, Kim HJ, Park J, Hwang J, Kim JI, Choi MG, Kim S, Kim KM, Kang MS. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology. 2015 Jan;148(1):137-147.e9. doi: 10.1053/j.gastro.2014.09.020. Epub 2014 Sep 22.</citation>
    <PMID>25254613</PMID>
  </reference>
  <reference>
    <citation>Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S, Liu Y. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS One. 2015 Sep 11;10(9):e0136476. doi: 10.1371/journal.pone.0136476. eCollection 2015.</citation>
    <PMID>26361042</PMID>
  </reference>
  <reference>
    <citation>Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec;33(9):983-90. doi: 10.1097/CJI.0b013e3181f3cbf4.</citation>
    <PMID>20948438</PMID>
  </reference>
  <reference>
    <citation>Lloyd A, Vickery ON, Laugel B. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol. 2013 Aug 5;4:221. doi: 10.3389/fimmu.2013.00221. eCollection 2013.</citation>
    <PMID>23935598</PMID>
  </reference>
  <reference>
    <citation>Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, Sha H, Cheng L, Meng F, Zou Z, Huang X, Liu B. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016 Jan 28;6:20070. doi: 10.1038/srep20070.</citation>
    <PMID>26818188</PMID>
  </reference>
  <reference>
    <citation>Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013 Oct;10(10):957-63. doi: 10.1038/nmeth.2649. Review.</citation>
    <PMID>24076990</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Yang Yang</investigator_full_name>
    <investigator_title>MD, PhD, MSCR</investigator_title>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>CRISPR Cas9</keyword>
  <keyword>EBV</keyword>
  <keyword>advanced stage malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

